 |
||||
| 2008 JASN IMPACT FACTOR 7.505 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2008 JASN IMPACT FACTOR 7.505 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FRONTIERS IN NEPHROLOGY |
Department of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada
1 To whom correspondence should be addressed. E-mail: bryce.kiberd{at}dal.ca.
 |
Abstract |
|---|
Estimating the prevalence of chronic kidney disease (CKD) is no simple task. The overall prevalence is relatively low but may be higher in select populations that are not accessible to surveys (e.g., certain ethnic groups, the sick or elderly). Moreover, the tests that define CKD lack precision and transportability to healthy populations. During the past decade, it is not clear that CKD has grown substantially. Some epidemiologic factors that are associated with CKD (obesity and diabetes) are increasing, whereas others (uncontrolled hypertension and smoking) are decreasing. Reasons for the discrepancy between a stable CKD population and ongoing ESRD growth remain speculative. There is evidence that ESRD rates may be stabilizing and that efforts to reduce progression in high-risk groups may be starting to show benefit. Expanding the definition of CKD and increasing detection may be required to reduce overall ESRD prevalence. One concern is that many of the well-defined high-risk patient groups (diabetes and black) are still undertreated. Increasing the investigation and treatment of low-risk patients may not be the answer. Clinical inertia (failure to initiate or change therapy) may be a more significant and modifiable barrier toward reducing ESRD, and this deserves increased attention. Furthermore, reducing CKD prevalence will require controlling the precipitating causes. The incremental benefit of detecting CKD in low-risk patients, use of expensive therapies in CKD, or new strategies such as the treatment of prehypertension require solid evidence, not only of the variety that shows benefit (hard end points) but also to whom, when, and at what cost.
This article has been cited by other articles:
 |
|
 |
|
  S. Kramer, E. Binder, T. Loof, Y. Wang-Rosenke, S. Martini, D. Khadzhynov, K. Budde, H.-H. Neumayer, and H. Peters The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy Am J Physiol Renal Physiol, July 1, 2009; 297(1): F218 - F227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Anderson, J. B. Halter, W. R. Hazzard, J. Himmelfarb, F. M. Horne, G. A. Kaysen, J. W. Kusek, S. G. Nayfield, K. Schmader, Y. Tian, et al. Prediction, Progression, and Outcomes of Chronic Kidney Disease in Older Adults J. Am. Soc. Nephrol., June 1, 2009; 20(6): 1199 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Young, S.-J. Hwang, M. J. Sarnak, U. Hoffmann, J. M. Massaro, D. Levy, E. J. Benjamin, M. G. Larson, R. S. Vasan, C. J. O'Donnell, et al. Association of Visceral and Subcutaneous Adiposity with Kidney Function Clin. J. Am. Soc. Nephrol., November 1, 2008; 3(6): 1786 - 1791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Glassock and C. Winearls An epidemic of chronic kidney disease: fact or fiction? Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1117 - 1121. [Full Text] [PDF]
|
|
|
|
|
|
S. V. Shah, J. Feehally, and on behalf of the World Kidney Day Steering Committ The Third World Kidney Day: Looking Back and Thinking Forward Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 309 - 311. [Full Text] [PDF]
|
|
|
|
|
|
C. L. Davis, W. E. Harmon, J. Himmelfarb, T. Hostetter, N. Powe, P. Smedberg, L. A. Szczech, P. S. Aronson, and for the American Society of Nephrology Public Poli World Kidney Day 2008: Think Globally, Speak Locally J. Am. Soc. Nephrol., March 1, 2008; 19(3): 413 - 416. [Full Text] [PDF]
|
|
|
|
|
|
N. Richards, K. Harris, M. Whitfield, D. O'Donoghue, R. Lewis, M. Mansell, S. Thomas, J. Townend, M. Eames, and D. Marcelli The impact of population-based identification of chronic kidney disease using estimated glomerular filtration rate (eGFR) reporting Nephrol. Dial. Transplant., February 1, 2008; 23(2): 556 - 561. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V. Shah and J. Feehally The third World Kidney Day: looking back and thinking forward Nephrol. Dial. Transplant., February 1, 2008; 23(2): 471 - 473. [Full Text] [PDF]
|
|
|
|
|
|
S. R. Orth and S. I. Hallan Smoking: A Risk Factor for Progression of Chronic Kidney Disease and for Cardiovascular Morbidity and Mortality in Renal Patients Absence of Evidence or Evidence of Absence? Clin. J. Am. Soc. Nephrol., January 1, 2008; 3(1): 226 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. G. Couser Chronic Kidney Disease The Promise and the Perils J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2803 - 2805. [Full Text] [PDF]
|
|
|
|
 |
|
 F. W Maddux, S. Shetty, M. A del Aguila, M. A Nelson, and B. M Murray Effect of Erythropoiesis-Stimulating Agents on Healthcare Utilization, Costs, and Outcomes in Chronic Kidney Disease Ann. Pharmacother., November 1, 2007; 41(11): 1761 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2009 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
